Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01779440 · ClinicalTrials.gov registry record · NA

Decision Support for Smoking Cessation in Young Adults With Severe Mental Illness

A NA study, sponsored by Dartmouth-Hitchcock Medical Center.

Completed
Registry status
NA
Development phase
58
Enrollment target

NCT01779440: Completed NA study, sponsored by Dartmouth-Hitchcock Medical Center.

NCT01779440 is a NA study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 58 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01779440, a NA study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.

COMPLETED
Registry status
NA
Development phase
58 participants
Enrollment target

Study Summary

Up to 77% of young people with severe mental illnesses smoke, a rate that is up to five times higher than the rate of daily smoking in other young adults. Contrary to popular belief, smoking tobacco does not provide any benefit for mental illness symptom control. People with severe mental illnesses (SMI: schizophrenia and severe mood disorders) are dying, on average, 25 years earlier than those without SMI. Much of this early mortality is due to higher rates of heart and lung diseases, cancers, strokes, and diabetes. Cessation of smoking in these transition-age young adults can prevent cancer and increase life expectancy to that of non-smokers. Combination treatments are effective in this group and therefore key to improving outcomes, but few SMI smokers use them despite their interest in quitting. Motivational interventions for cessation increase interest in quitting, but public mental health clinicians do not deliver them, in part due to economic reasons. Thus cost effective methods to deliver motivational interventions to engage young smokers with SMI into treatment are needed. To address this gap, we have developed an electronic decision support system (EDSS) for smoking cessation that is specifically tailored for smokers with SMI, who tend to have cognitive deficits and limited computer experience. Similar to EDSSs developed for other health problems, this EDSS provides information and motivational exercises within an easy-to-use, web-based computer program that can be used with minimal or no staff assistance. Initial piloting of the EDSS in middle-aged SMI smokers showed excellent usability and promising efficacy. Pilot-testing among young patients suggested that the EDSS increased motivation to quit smoking and provided direction to adapt the format and content of the EDSS for young SMI smokers. The purpose of this proposal is to further develop the motivational decision support system and to test its ability to motivate young smokers with SMI to quit smok

Primary Outcome

Assesses through clinician confirmation any engagement in behavioral smoking cessation treatment and/or smoking cessation medication treatment.

Interventions

  • BEHAVIORAL Electronic Decision Support System

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2013-01-01
Est. Completion 2018-02-22
Phase NA
Dartmouth-Hitchcock Medical Center

427 total trials

What the finished NCT01779440 record still lists

NCT01779440 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 1 intervention - of which Electronic Decision Support System is the first listed.

NCT01779440 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01779440 about?

NCT01779440 is a clinical study titled "Decision Support for Smoking Cessation in Young Adults With Severe Mental Illness". Up to 77% of young people with severe mental illnesses smoke, a rate that is up to five times higher than the rate of daily smoking in other young adults. Contrary to popular belief, smoking tobacco does not provide any benefit for mental illness symptom control. People with severe mental illnesses ...

What is the current status of trial NCT01779440?

This trial is currently completed. It is a NA study. The enrollment target is 58 participants. The study started on 2013-01-01. Estimated completion is 2018-02-22.

What interventions are being tested in trial NCT01779440?

The interventions under investigation include: Electronic Decision Support System (BEHAVIORAL).

Who is sponsoring clinical trial NCT01779440?

This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01779440's enrollment target sits among peer trials

58 1256th of 2000 higher than 740 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03587844 · 58 participants · Phase 2

    Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

  • NCT03630991 · 58 participants · Phase 1

    Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

  • NCT03949855 · 58 participants · Phase 2

    Belimumab With Rituximab for Primary Membranous Nephropathy

  • NCT04069273 · 58 participants · Phase 2

    Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01779440, the US trial registry maintained by the National Library of Medicine. NCT01779440 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.